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39.1.1  General Concepts
Toxoplasma gondii is a protozoan that commonly 
infects animals and birds. Primary T. gondii 
infection in humans and other mammals is usu-
ally asymptomatic but leads to lifelong latent 
infection. Transmission to humans occurs by 
ingesting tissue cysts from undercooked meat or 
oocysts (released in the feces of cats). Latent 
cysts can give rise during immunosuppression to 
a severe localized reactivation producing, for 
example, toxoplasma encephalitis or chorioreti-
nitis, with dissemination being common. 
(Martino et  al. 2000; Martino et  al. 2005; 
Tomblyn et al. 2009; Martino 2016).
Although toxoplasmosis is the most common 
systemic parasitic infection in EBMT centers, it 
is a relatively rare opportunistic infection follow-
ing HSCT.  Currently we are aware that the 
patients’ seroprevalence explains the wide range 
of incidences published. Table 39.1 summarizes 
selected case series of toxoplasmosis in HSCT 
published to date.
39.1.2  Risk Factors and Incidence 
in HSCT
The seroprevalence for T. gondii varies greatly 
between and even within countries, ranging from 
<15% in Japan and in pediatric wards, 30% in 
urban adults in North America and the UK, and to 
40–80% of adult HSCT recipients in countries 
with high endemicity such as France or Turkey. 
This varying seroprevalence is the main reason 
for the great variability in the incidence of toxo-
plasmosis after HSCT, which has been estimated 
to average 0.8%, with <0.4% in areas of low 
endemicity to 2–3% in those with high-antibody 
prevalence.
Toxoplasmosis occurs mainly in allo-HSCT 
recipients, although cases after auto-HSCT have 
been published. Reactivation of latent tissue cysts 
in previously infected individuals is the usual 
mechanism implicated. Thus, it is important to 
determine the patients’ serostatus prior to trans-
plant. However, the disease may also develop if 
primary (or re-)infection after transplant may 
occur.
Ninety-five percent of the cases occur within 
the first 6 months after the procedure, and acute 
GVHD and its treatment are the main risk factors. 
Late cases may occur, again usually in patients 
with chronic GVHD requiring IST.  In addition, 
seropositive patients without GVHD but with 
severe cellular IS due to in vivo or ex vivo TCD 
are also at risk.
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39.1.3  Most Common Clinical 
Presentations
The CNS is the main site of disease, but pneumo-
nitis and myocarditis are also frequent findings.
Toxoplasma encephalitis typically presents 
with focal neurologic abnormalities of subacute 
onset, frequently accompanied by non-focal signs 
and symptoms such as headache, altered mental 
status, and fever. Meningeal signs are very rare. 
CT brain scans often show multiple bilateral cere-
bral lesions, although MRI is more sensitive than 
CT in the early diagnosis of this infection. 
Toxoplasma pneumonitis may develop in the 
absence of extrapulmonary disease. Toxoplasma 
chorioretinitis is rare compared to AIDS patients.
39.1.4  Diagnosis
In HSCT recipients, the utility of serology is 
mainly to identify those at risk for developing 
toxoplasmosis post transplant.
PCR techniques are currently the standard 
method for its diagnosis. These techniques are 
applicable in blood, CSF, and BAL, the usual 
samples that are available in HSCT recipients 
with this infection. Most centers use qPCR with a 
level of detection as low as 20 parasites/mL, with 
parasite loads of >600/mL reported in most 
patients with toxoplasmosis.
Since histologically proven toxoplasmosis is a 
very difficult-to-obtain diagnosis, various levels 
of diagnostic certainty have been proposed. 
Histologically defined cases are considered as 
definite cases of toxoplasma disease, PCR- 
defined cases as probable, and CNS imaging- 
defined cases as possible ones.
39.1.5  Treatment and Prognosis
Table 39.2 details the recommended treatment 
and prophylaxis of toxoplasmosis in HSCT 
recipients. Most patients respond to one or 
another of these regimens, and neurologic 
improvement of toxoplasma brain involve-
ment usually occurs within 7  days. If appro-
priately treated, up to 60% of patients may 
show clinical–radiologic improvement or even 
a complete response to therapy. This high-
lights the  importance for a high index of suspi-
cion for toxoplasmosis in immunocompromised 
patients.
Table 39.1 Selected case series of toxoplasmosis after HSCT (Martino 2017)
Author (year)a Cases
Number of HSCT (% 
frequency) % of sero (+) pre-HSCT
Median (range) 
day onset
Derouin et al. (1992) 7 296 allo (2.4) 65 74 (55–180)
Slavin et al. (1994) 12 3.803 allo (0.31)
509 auto (0)
15 59 (35–97)
Bretagne et al. (1995) 2 550 allo (0.3) 70 NS
Maschke et al. (1999) 20b 655 (3.1) NS 73 (14–689)





Small et al. (2000) 10 463 allo (2.2) 23 78 (36–155)
Aoun et al. (2006) 7 121 allo (5)
204 auto (0.4)
69 45 (13–140)
de Medeiros et al. (2001) 9 789 allo-HSCT (1.14) NS 69 (13–265)
Mulanovich et al. (2011) 9 3.626 Allo (0.25)
  – U.S. pt 0.15%




Bautista et al. (2012) and Martino 
et al. (2015)
9 148 adult CBT (4%) 45 39 (7–98)
Sumi et al. (2013) 6 279 allo (1.8%)
87 auto (1.1%)
10 NS
Hakko et al. (2017) 5 170 allo (2.9%) 70 42 (26–119)
aNot all in references
b4 definite and 16 possible cases of toxoplasmosis
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39.1.6  Specific Screening and/or 
Prophylactic Strategies 
Available
Current data suggest that infection may precede 
disease in most cases of toxoplasmosis. Thus, mon-
itoring sero(+) patients with weekly qPCR of blood 
samples has been advocated, especially when pro-
phylaxis is not being used, in an effort of using a 
preemptive-type therapeutic approach, as used for 
CMV infection. Although an optimal qPCR tech-
nique has not been standardized, several studies 
support the usefulness of this approach. Patients on 
TMP/SMX prophylaxis should not be monitored.
TMP/SMX is useful in minimizing the risk of 
reactivation of toxoplasmosis, although there are 
well-reported cases of toxoplasmosis breaking 
through this prophylaxis in HSCT recipients. 
Suboptimal dosing may have contributed to some 
of these “breakthrough” infections, since these 
cases occur when TMP/SMX is taken less than 
3 days per week. Thus, using either one standard- 
dose tablet (80/400 mg) daily or a double-strength 
tablet (160/800 mg) 4 days per week is the recom-
mended dosing, as shown in Table 39.2.
Avoiding primary or reinfection after HSCT is 
always important, avoiding the most common 
sources of infection: uncooked meats of any type 
and drinking contaminated water.
39.2  Tuberculosis (TBC)
(de la Cámara et al. 2000; Cordonnier et al. 2004; 
Yao-Chung et  al. 2016; Young and Weisdorf 
2016; Beswick et al. 2018).
39.2.1  General Concepts
TBC, and especially, multidrug-resistant (MDR) 
TBC, continues to be a worldwide major health 
problem. This may surprise many EBMT HSCT 
physicians, who may have never seen a case of TBC.
39.2.1.1  Mycobacterium Tuberculosis
Mycobacterium tuberculosis causes nearly all 
cases of TBC, and these acid-fast bacilli differ 
from other bacteria in that they can live only in an 
infected human. Outside of the human body, they 
have a very short survival, and infection is trans-
mitted by the inhalation of aerosolized particles 
from a patient. In addition, its isolation from clini-
cal samples should never be considered as a colo-
nization or sample contamination. TBC is not an 
opportunistic infection, and thus its detailed 
description is outside the scope of this manual.
39.2.2  Risk Factors and Incidence 
in HSCT
The risk of developing TBC is directly proportional 
to the TBC present in the geographic area of the 
HSCT center and the patients’ residence (Fig. 39.1). 
A few studies have analyzed its incidence with 
respect to the general population, and most have 
found that allo-HSCT recipients have 2–10 times 
higher risk than the general population, while auto-
HSCT recipients do not have a significantly higher 
risk (De la Cámara et al. 2000) (Table 39.3).
Table 39.2 Suggested treatment and prophylaxis for 




Oral, 200 mg loading dose, then 
50–75 mg q.d. (folinic acid, oral 
or IV, 10–15 mg q.d.) + one of 
the following
Sulfadiazine Oral, 1–1.5 g q6–8h, OR
Clindamycin Oral or IV, 600 mg q6h
Prophylaxis Dose
TMP/SMXa,b 1 double-strength tablet 
(160/800 mg)/day, 4 day × week, 
OR
2 double-strength tablets 
(160/800 mg)/day, 3 day × week, 
OR





2–3 tables per week
Dapsoneb 100 mg daily
Atovaquoneb 1500 mg daily
aAlso effective for PJP prophylaxis, and possibly listerio-
sis, nocardiosis, and, in some geographic areas, partly 
effective in preventing gram-positive cocci and gram- 
negative bacillary (enterobacterial and non-glucose fer-
menting) infections
bThe dose can be reduced in patients with mild renal 
insufficiency












Fig. 39.1 TBC estimate incidence rate 2016 (WHO webpage)
Table 39.3 Selected case series of mycobacterial infections after HSCT before 2018
Author (year)a Country
TBC/HSCT x risk with 
GPb




Lee et al. (2017) Korea 21/824 (allo) × 9.1 GP NA 1 died
Liu et al. (2016)c Taiwan 5/422 (allo) 21/422 (allo) 11 died
Beswick et al. (2018) Canada NA 30/1097 (allo) × 35 GP NA





USA 4/577 (allo) × 10 GP 0 NA





Ku et al. (2001) Taiwan 8/255 (allo) × 13.1 GP
0/95 (auto)
0 ND





Turkey 5/351 (allo) × 3.9 GP 0 No deaths
Gaviria et al. (2000) USA 3 /6529 (3 allo) 0 No deaths
Aljurf et al. (1999) Saudi Arabia 4/641 (allo) 0 2 died










NA Details not available in the study
aNot all in references
bx risk with GP, studies in which the relative risk of suffering TBC was compared to that in age-/sex-matched normal 




39.2.3  Most Common Clinical 
Presentations
The clinical presentation of TBC in HSCT recipi-
ents is the same as in the general population, 
although it may have a more rapid progression, 
and the ratio of pulmonary to extrapulmonary 
disease has been reported 34/5 to 11/10, which 
surely represents a publication bias, with a 
median of 75%/25%. The most common extra-
pulmonary disease is meningitis.
39.2.4  Diagnosis
Culture of even a single colony from an affected 
organ is diagnostic for TBC. Direct microbio-
logic examination for acid-fast bacilli is of 
course mandatory, but its sensitivity is probably 
low. In addition, the results of positive cultures 
take many days to weeks, and the use of highly 
sensitive and specific PCR methods is now the 
usual methods for the initial diagnosis.
The quantiFERON-TB Gold test is not reli-
able in the diagnosis of TBC in HSCT recipients 
due to their T-cell immunodeficiency.
39.2.5  Treatment and Prognosis
With appropriate treatment, TBC in HSCT recipi-
ents has a low attributable mortality (<30%). The 
author suggests that HSCT physicians contact ID 
physicians immediately when diagnosis of TBC is 
made. Empirical treatment should be started if 
this consultation will not be replied immediately, 
but herein we cannot recommend a “one fits all” 
drug combination, since this varies greatly accord-
ing to the level of drug resistance in each geo-
graphical area.
39.2.6  Specific Screening and/or 
Prophylactic Strategies 
Available
Even in areas where TBC is endemic, pre-
HSCT screening with the tuberculin skin test 
or the gamma-interferon quantiFERON-TB 
Gold test is not done in most HSCT centers. In 
addition, specific antibiotic prophylaxis in 
patients with past and cured TBC is not 
warranted.
Two special scenarios do, however, require 
contacting an ID specialist pre- or post-HSCT 
in order to analyze whether “prophylaxis” may 
be indicated, the drugs to use, and their 
duration:
 1. Highly IS HSCT recipients or candidates who 
have been substantially exposed to someone 
with active infectious TBC
 2. HSCT recipients or candidates with a positive 
tuberculin skin test or the gamma-interferon 
quantiFERON-TB Gold test who were not 
previously treated and have radiological evi-
dence of TBC lung disease
39.3  Nontuberculous (or Atypical) 
Mycobacterial (NTM) 
Infections
(Cordonnier et  al. 2004; Young and Weisdorf 
2016; Beswick et al. 2018).
39.3.1  General Concepts
Atypical mycobacteria are fastidious microor-
ganisms that are ubiquitous in nature and can 
simply colonize any body surface and secretions 
and often contaminate clinical samples from the 
environment. There are a very large number of 
NTM species with varying geographical distribu-
tions. However, with respect to infections in 
HSCT recipients, NTM can be divided into two 
different categories:
 (1) Mycobacterium avium-intracellulare complex.
 (2) Anonymous or atypical NTM, subdivided 
into the rapidly growing NTM and the slow 
growing NTM: the most commonly reported 
species from EBMT centers are M. fortui-
tum, M. chelonae, M. abscessus, M. xenopi, 
and M. kansasii.
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39.3.2  Most Common Clinical 
Presentations and Risk Factor
A large number of atypical NTM infections are 
CVC infections, followed by skin infections. 
However, in patients with severe cGVHD, severe 
infections of any organ can occur, as well as dis-
seminated cases. M. avium-intracellulare com-
plex, on the other hand, usually causes pulmonary 
disease or disseminated infections, with blood 
cultures being positive in >50% of cases. Such 
infections almost always occur in severely immu-
nocompromised allo-HSCT recipients, such as 
those with severe steroid-dependent cGVHD.
39.3.3  Diagnosis
Diagnosis requires isolation of a NTM from the 
affected organ(s). Differentiating colonization 
from contamination and disease can be difficult 
with NTM. Depending on the species, cultures can 
be positive in very few days or take many days, as 
with TBC. Thus, the use of specific PCR methods 
and/or special biochemical methods is now the 
usual method for the diagnosis of NTM infections.
39.3.4  Treatment and Prognosis
With appropriate treatment, most NTM infec-
tions have a good outcome and a low attributable 
mortality, although the data are very scarce 
(Table 39.3).
As in the case of TBC, the author suggests that 
HSCT physicians contact ID physicians immedi-
ately when diagnosis of NTM infection is made. 
In CVC infections, the catheter should probably 
always be removed. While awaiting for the ID 
specialists, empirical therapy with a macrolide 
(clarithromycin or azithromycin) plus moxifloxa-
cin or levofloxacin can be started.
39.3.5  Specific Screening and/or 
Prophylactic Strategies 
Available
Screening and prophylaxis have no role in NTM 
infections.
39.4  Listeriosis
(Safdar et  al. 2002; Boyle 2014; Martino et  al. 
1996).
39.4.1  General Concepts
Only one species, Listeria monocytogenes, pro-
duces all cases of this mostly “bacterial food-
borne” infection. L. monocytogenes is a 
pseudo-“diphtheroid” gram-positive bacillus. 
This organism is widespread in nature and in tap 
water, sewage, the microbiota of pets and farm 
animals, and nearly all types of fresh foods. The 
fact that it grows well in refrigerator tempera-
tures adds yet another variable which favors 
ingestion by humans, which appears to be univer-
sal worldwide. At any specific moment, 5% of 
healthy humans have L. monocytogenes in feces. 
With these premises, it is surprising that listerio-
sis is an uncommon infection in HSCT 
recipients.
39.4.2  Risk Factors and Incidence 
in HSCT
The only risk factor is the combination of ingest-
ing colonized food or water and having a severe 
cellular IS.
Its incidence is unknown, and only two studies 
are available. At the MSKCC in New York, six 
cases occurred in 1315 allo-HSCT recipients 
from 1985 to 1997, with an incidence of 0.47% 
(Safdar et  al. 2002). At the FHCRC in Seattle, 
three cases occurred among 4069 HSCT recipi-
ents (<0.1%) during the first 100 days post trans-
plant (Boyle 2014). Finally, in our center, we 
have had three cases of listeriosis among 2360 
adult HSCT recipients (0.1%) (Martino et  al. 
1996). All other information has been reported as 
isolated case reports.
39.4.3  Most Common Clinical 
Presentations
Listeriosis in HSCT recipients is almost always a 
sepsis syndrome with bloodstream infection, 
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with CNS involvement in 40–60% of cases, 
which can present as meningitis, encephalitis, or 
brain abscess, and with several cases of rhomben-
cephalitis reported (Chang et al. 1995).
39.4.4  Diagnosis
The diagnosis is made after the bacterial microbi-
ology laboratory informs the clinicians that the 
patient has positive blood and/or CSF cultures for 
this organism. The putative source of the infec-
tion cannot be identified in outpatients.
39.4.5  Specific Screening and/or 
Prophylactic Strategies 
Available
Screening has no role in preventing listeriosis. 
Standard approaches to food safety handling and 
preparation are, of course, the main preventive 
measures.
The routine use of TMP/SMX prophylaxis 
after HSCT surely has a role in preventing liste-
riosis, but its low incidence makes this impossi-
ble to prove.
Cases of listeriosis in long-term inpatients 
should, of course, activate the rapid intervention 
of the hospital infection control/prevention unit 
in the HSCT ward.
39.4.6  Treatment and Prognosis
The treatment of choice is high-dose ampicillin 
(or high-dose TMP/SMX in those allergic to pen-
icillin) combined with an aminoglycoside during 
3 weeks or 6 weeks in case of CNS infection. We 
also recommend consultation with ID 
specialists.
The prognosis of listeriosis in HSCT recipi-
ents is unknown, although 20% of the reported 
cases died, while 10% had a CNS recurrence.
39.5  Nocardiosis
(Coussement et  al. 2017; Shannon et  al. 2016; 
Bambace et al. 2013).
39.5.1  General Concepts
Nocardia spp. (any of the dozens of currently 
accepted species may be involved, but most cases 
in Europe appear to be due to N. asteroides, N. 
brasiliensis, and N. nova) are aerobic gram- 
positive rods that grow in characteristic filamen-
tous, branching chains and being acid fast, and 
their appearance makes them easily identifiable 
by microbiologists, with its acid-fast staining 
properties differentiating it from Actinomyces 
spp. Nocardia spp. grow in soil and decaying 
matter, and human infection usually occurs from 
inhalation of airborne bacilli.
39.5.2  Risk Factors and Incidence 
in HSCT
Nocardiosis is a late post-HSCT infection, occur-
ring months to years after HSCT, mostly allo- 
HSCT.  Patients usually have steroid-dependent 
chronic GVHD, secondary diabetes mellitus, 
and/or bronchiolitis obliterans or bronchiectasis 
from the numerous post-HSCT infections suf-
fered. There are no specific risk factors in HSCT, 
although being at the right time in a place where 
soil-living bacilli are made massively airborne is 
a common-sense mechanism of infection. Similar 
to M. tuberculosis, Nocardia spp. do not colonize 
the airways.
The incidence of nocardiosis has been reported 
to range from 0.3 to 1.7% in allo-HSCT, although 
many large centers have not had a single case. In 
auto-HSCT the median incidence is 0%, although 
occasional cases have been reported and surely 
occur in many centers.
39.5.3  Most Common Clinical 
Presentations
Pulmonary infection, with its accompanying 
signs and symptoms, and radiologically one or 
more nodular lesions with a tendency to cavitate 
occur in 90% of patients with nocardiosis. At pre-
sentation, however, around half of the patients 
have disseminated disease, usually to the skin 
and osteoskeletal organs, but around 1/3 will 
have CNS involvement up front. Since CNS 
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involvement is so common and can initially be 
asymptomatic, a CNS CT or MRI scan is manda-
tory in all HSCT recipients with pulmonary 
nocardiosis (in any IS host, in fact). Brain 
abscesses are the usual presentation, although 
severe hyponatremia due to SIADH is also com-
mon due to basal meningitis.
39.5.4  Diagnosis
Diagnosis, of course, requires culture of an 
affected organ, usually the lungs. Often, the char-
acteristic ramified bacilli can be directly observed 
from sputum or a directed BAL, but culture- 
based diagnosis is made in at least 1/3 of the 
cases. This is of utmost importance, since cul-
tures become positive at a median of 9 days after 
sampling but can take up to 2–4  weeks. 
Molecular-based methods are useful only to 
identify uncommon species of Nocardia with 
known multidrug resistance, but this is rarely 
required in clinical practice. The most common 
differential diagnosis is with invasive pulmonary 
mold infections.
39.5.5  Specific Screening and/or 
Prophylactic Strategies 
Available
Screening has no role in preventing nocardiosis, 
but its rapid diagnosis does have an impact on 
patient outcome.
The routine use of TMP/SMX prophylaxis 
after HSCT may prevent more cases of nocardio-
sis, but the 2–3-day per week schedules are not 
effective in preventing it. Of note, Nocardia spp. 
isolated in patients taking single-strength TMP/
SMX prophylaxis 5–7 days per week have had a 
good in  vitro susceptibility to TMP/SMX and 
have responded well to high doses of the drug.
39.5.6  Treatment and Prognosis
High-dose TMP/SMX is still the treatment of 
choice, although there have been good results 
with carbapenems, amikacin, second-generation 
cephalosporins, and/or linezolid.
When treated promptly, nocardiosis usually 
resolves with prolonged antibiotic therapy, but 
directly attributable mortality has been reported 
in up to 40% of cases; these are, of course, those 
cases that affect extremely debilitated allo-HSCT 
recipients due to prolonged severe GVHD and its 
numerous complications, as well as those with 
disseminated infection and extensive CNS 
involvement, including the brain stem. Overall 
mortality, however, is high, since around 40% of 
patients have severe coinfections when nocardio-
sis joins the club.
Treatment of nocardiosis usually requires at 
least 6 months of specific antibiotic therapy, and 
it is of course recommended that ID specialists 
are actively involved in the treatment and follow-
 up. Of note, most Nocardia isolates are suscepti-
ble to most of the too-often empirically/
prophylactically used antibiotics in HSCT recipi-
ents (levofloxacin, moxifloxacin, amoxicillin- 
clavulanate), as well as tetracyclines and 
tigecycline.
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